Left atrial appendage occlusion vs continuation of oral anticoagulation therapy alone is linked to reduced ischemic stroke risk in select patients with nonvalvular AF.

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Next-generation system to be highlighted during a technology innovation session and live case presentation by Professor Jens Erik Nielsen-Kudsk "We are pleased that the CLAAS AcuFORM system is ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Next-generation system to be highlighted during a technology innovation session and live case presentation by Professor Jens Erik Nielsen-Kudsk "We are pleased that the CLAAS AcuFORM system is ...

Next-generation system to be highlighted during a technology innovation session and live case presentation by Professor Jens Erik Nielsen-Kudsk "With a single size, the CLAAS® AcuFORM™ implant ...

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

Cardiologist Dr. Josiah Brown, specializing in minimally invasive therapies, is the newest team member at Alaska Heart & ...

Left atrial appendage occlusion (LAAO) device is an alternative approach to prevent strokes in patients who cannot tolerate anticoagulation. Patients undergoing LAA electrical isolation (LAAEI) as ...